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Rationale, aims and objectives: Although medicine review services are offered by community 
pharmacists in many countries, they are non-existent in Italy.  A novel intervention I-MUR, was 
developed for patients with asthma aiming to improve medicines use. The aim of this study was to 
obtain pharmacists’ and patients’ views on the acceptability of the I-MUR service provided by 
community pharmacists to asthma patients in four regions of Italy.   
Methods: Pharmacists’ expectations, experiences and attitudes to delivering the I-MUR were obtained 
through questionnaires distributed before and after delivering the I-MUR, plus focus groups. Patients’ 
views were obtained via questionnaires, distributed by the pharmacists and returned anonymously.  
Results: Seventy-four pharmacists provided the I-MUR service to 895 asthma patients; 49 pharmacists 
completed both questionnaires, 53 participated in focus groups and 246 patients returned 
questionnaires. Barriers anticipated most frequently by pharmacists before the I-MUR were lack of 
time (53%) and lack of co-ordination with other health professionals (61%), while lack of financial 
compensation was identified by 37%. Lack of co-ordination proved the most common actual barrier 
(88%), with lack of financial compensation being cited less frequently after providing the intervention 
(8%). Ninety-six percent of pharmacists anticipated providing both education on inhaler technique and 
medication counselling, but in practice slightly fewer had provided these (90% and 86% respectively). 
Focus groups highlighted a lack of relevant undergraduate education to support medication review 
and structural barriers within some pharmacies, but described positive patient feedback and desire to 
extend the I-MUR. Patients’ respondents were positive; 62% indicated the reason for having an I-MUR 
as making sure that they were using medication correctly, 75% considered they benefited from it and 
86% would recommend it to others. 
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Conclusions: The I-MUR service was perceived positively by both pharmacists and patients, supporting 
the extension of medicine review services to community pharmacists in Italy.  
 
Introduction 
Community pharmacists play an important role as health care providers in many countries, such as 
USA, Canada, Australia, UK, Denmark, Netherlands, and Switzerland, where pharmacists providing 
pharmaceutical care and/or cognitive pharmaceutical services are remunerated by public or private 
payers. They are easily accessible, because pharmacies are situated in both small and large centres of 
population and in rural areas. In England 89% of the population has access to a community pharmacy 
within 20 minutes’ walk,1 and, although no similar data are available, accessibility is similar in Italy. 
While cognitive pharmaceutical services are increasingly common across the world, in Italy, no services 
were commissioned or funded. In 2012, the Italian Pharmacists’ Federation (FOFI) decided to support 
a project aiming to introduce the first cognitive pharmaceutical service in Italy. This new service was 
based on the English Medicines Use Review (MUR) service which was introduced in 2005,2 but was 
specifically tailored for patients with asthma. It was called the Italian Medicines Use Review (I-MUR) 
and involved a bespoke pharmacist-led consultation which consisted of a systematic, structured 
interview, conducted in a private room within the pharmacy, which covered asthma symptoms, 
medicines used, attitudes towards medicines and adherence. 
The development, testing and evaluation of I-MUR, as with any new intervention, required that 
acceptability of the service to the two main stakeholders, pharmacists and patients, be assessed. Many 
studies in England have sought the views of patients on medication review services, delivered by 
pharmacists in both general practice surgeries and in community pharmacies,3-6 while other studies 
have sought the views of pharmacists.4,7 Few studies have reported the views of both pharmacists and 
patients on pharmacy services,8,9 although one study in England compared the views of pharmacists 
with the general public on medication-related services,10 including the MUR. No studies have explored 
the views of either patients or pharmacists on any services provided by community pharmacists in 
Italy.  
The study aimed to obtain pharmacists’ and patients’ views on the acceptability of the I-MUR service 
provided by Italian community pharmacists.  
Methods 
Setting and participants 
All community pharmacists who took part were working in one of the four regions of Italy where the 
study took place: Brescia (Lombardia), Torino (Piemonte), Pistoia (Tuscany), Treviso (Veneto). All had 
undergone screening by their local pharmacy organisation to ensure the suitability of the individual 
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and their pharmacy premises for delivering the I-MUR.11 Pharmacists received training in the provision 
of I-MUR before recruiting patients; then they recruited potential patients for the I-MUR service who 
were adults with a diagnosis of asthma, for at least six months and using a prescription(s) for asthma 
or drugs for obstructive airways disease.  
Pharmacist views were obtained by two methods: questionnaires distributed before and after 
delivering the I-MUR, followed by focus groups. Patient views on the I-MUR were obtained via a 
questionnaire survey, distributed by the pharmacists, nine months after delivery ceased (October –
November 2013). 
Instruments 
Pharmacist questionnaire 
 A questionnaire was developed based on an instrument used in a previous study in England (Jaffray 
et al. 2007).12 It was divided into three sections: pharmacists’ demographic details; expectations and 
experiences of delivering the I-MUR service; views about the I-MUR service using a five-point Likert 
scale plus confidence and comfort in delivering the intervention.  Expectations were sought by:  i) 
requesting respondents to select any issue from a list, developed from previous studies, which they 
thought may be potential barriers to providing the I-MUR and ii) to select the types of pharmaceutical 
care issues (PCIs) they thought may be identified in the patients, using a validated classification 
system.13 The post-I-MUR questionnaire asked respondents to select the actual barriers and actual PCIs 
they thought they had identified during I-MUR provision from the same lists. The pre-I-MUR 
questionnaire was distributed using the Qualtrics© on-line system one week prior to the I-MUR 
training (September 2012). The post-I-MUR questionnaire was distributed using the same method one 
week after delivery ceased (February 2013). 
Pharmacist focus groups  
Six key areas were used as a topic guide covering: a) feedback received from patients, b) pharmacists’ 
views about I-MUR, c) limitations of the service, d) barriers to providing the service, e) views on training 
provided, f) possible future application and developments.  
Patient questionnaire  
A questionnaire previously developed by Krska et al. (2009)14 for users of the English MUR service was 
adapted to capture patients’ view and experience with regards to the I-MUR service received. The 
questionnaire included patients’ demographic information, a list of potential benefits from which 
patients were asked to select those they anticipated the I-MUR  may result in and a series of 19 
statements about the I-MUR service received, which patients were asked  to rate using a five-point 
Likert scale: strongly disagree to strongly agree. In addition, it asked respondents to consider whether 
the I-MUR could be improved, if they would consider having another I-MUR and would recommend it 
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to others, each with space for adding reasons for their responses. A final open-ended question sought 
other comments. All pharmacists distributed paper questionnaires to all patients for whom they 
provided an I-MUR in October 2013, with envelopes for return to the pharmacy. Pharmacists sent the 
returned envelopes to their local pharmacy body for forwarding to the research team. 
Conduct of the focus groups 
Focus groups were held for pharmacists in each of the four regions of Italy, in February 2013, after 
pharmacists had stopped conducting I-MURs and completed the post-I-MUR questionnaire. Each focus 
group was audio recorded with permission, obtained as part of the pharmacists informed consent 
process at the start of the project. AM conducted all focus groups, using the topic guide, and a second 
pharmacist took field notes.  
Data Analysis 
Pharmacist Pre and Post I-MUR questionnaire   
Quantitative data gathered with the online questionnaires were analysed using SPSS 20.  McNemar’s 
or Fisher’s exact tests were used to compare responses to the questions covering 
expectations/experiences. Paired t-tests were used to assess changes in confidence and comfort with 
providing I-MUR.   
Pharmacist focus groups 
All focus group transcripts were in Italian. Framework analysis was used, based on the areas included 
in the topic guide. The verbatim transcripts of the focus groups were coded in QSR NVivo version 10, 
according to each topic area. Once the analysis was completed in Italian, the findings were translated 
into English by AM.  
Patient questionnaires  
Quantitative data gathered from returned patients’ questionnaires were manually entered into the 
online platform, enabling a preliminary descriptive statistical analysis, and then exported into SPSS 
version 21. Goodman and Kruskal’s gamma (γ) was used to assess the strength and direction of 
association that existed between two variables. Responses to free-text boxes embedded in the 
questionnaire were analysed thematically. 
Ethical approval, consent and anonymity 
The research was approved by the University of Kent Faculty of Science Research Ethics Committee. 
Pharmacists, after having assessed patients’ eligibility for the study, provided an information letter and 
obtained written consent for the I-MUR. These were retained along with patient contact details within 
the pharmacies, enabling pharmacists to distribute the questionnaire survey. Patients were instructed 
to return the questionnaire to their pharmacy in a sealed envelope, ensuring that their responses 
remained unknown to the pharmacist who provided the I-MUR. Implied consent was assumed by 
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return of completed questionnaires from both pharmacists and patients. Written consent was 
obtained from all pharmacists who took part in focus groups. 
Results 
Response rates 
Eighty pharmacists were enrolled, of whom 75 began the study and 74 (92.5%) completed it by 
delivering at least one I-MUR. Of the 74, 49 pharmacists (66%) returned both questionnaires allowing 
comparisons to be made pre- and post-delivery. The total number of pharmacists who participated in 
the focus groups was 53. Two focus groups were conducted in Treviso (Veneto region) involving five 
and six participants; three in Brescia (Lombardia region) each with six pharmacists; one in Torino 
(Piemonte region) with nine participants and three in Pistoia (Toscana region), with six, five and four 
participants. Out of the 895 patients who received the I-MUR service, 246 returned the completed 
questionnaire (27.4%). 
Pharmacist questionnaires 
There were similar numbers of pharmacists who provided the I-MUR across all four regions, however 
the proportion who returned both questionnaires from Treviso was lower than for other regions. 
(Table 1) In all other respects, the demographics of questionnaire respondents was representative of 
the pharmacists who provided the I-MUR. 
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Table 1 Demographic characteristic of pharmacists delivering I-MUR and completing 
questionnaires 
 
                         Characteristics 
N delivering I-MUR 
(%) 
N completing 
questionnaires 
(% of those 
delivering) 
Place of Work 
Brescia 19(25.3) 15(79.0) 
Pistoia 17(22.7) 12(70.6) 
Torino 20(26.7) 14(70.0) 
Treviso 19(25.3) 8(16.3) 
Gender 
Male 35(46.7) 24(68.6) 
Female 40(53.7) 25(62.5) 
Age 
24-30 10(13.3) 8(80.0) 
31-40 20(26.7) 11(55.0) 
41-50 25(33.3) 17(68.0) 
51-60 16(21.3) 11(68.8) 
61-65 2(2.7) 1(50.0) 
>65 2(2.7) 1(50.0) 
Role 
Owner 5(6.7) 2(40.0) 
Owner & Manger 34(45.3) 21(61.8) 
Manager 8(10.7) 6(75.0) 
Support Pharmacist 25(33.3) 
18(72.0) 
Locum 3(4.0) 2(66.7) 
Type of business 
Independent 64(85.3) 43(67.2) 
Small chain (1-4) 4(5.3) 2(50.0) 
Large chain (5 or 
more) 
7(9.3) 
4(57.1) 
Working hours 
Full time  72(96.0) 46(63.9) 
Part time 3(4.0) 3(42.9) 
Years since qualified 
<5yr 9(12.0) 6(66.7) 
5yr-15yr 24(32.0) 16(66.7) 
>15yr 42(56.0) 27(57.4) 
Postgraduate qualification  
Certificate 7(9.3) 4(57.1) 
Diploma 7(9.3) 5(71.4) 
Master 7(9.3) 6(85.7) 
Specialisation 8(10.7) 5(62.5) 
Doctorate 2(2.7) 2(100) 
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Potential and actual barriers to delivery  
All the potential barriers listed in the questionnaire were selected by some of the 49 pharmacist 
respondents before provision of the I-MUR, with those selected most frequently being lack of time (26; 
53%) and co-ordination with other health professionals (30; 61%). Both issues were found by more 
pharmacists to be actual barriers to I-MUR provision after delivering the service than had been 
anticipated, with the proportion citing lack of co-ordination rising to 43 (88%) (p= 0.01). Lack of 
personnel and resources was also cited slightly more frequently after I-MUR provision (11; 22%) 
compared to 16% (n=8) before I-MUR. Meanwhile lack of financial compensation (15; 37% vs 4; 8%), 
knowledge and skills (24.5% vs 14.3%), lack of clinical tools (22.5% vs 16.3%) and lack of space (6.1% 
vs 0) were all regarded as barriers by fewer pharmacists after providing the I-MUR than they had 
anticipated.  
Expectations and experiences of PCIs and interventions  
Pharmacists selected all 14 different types of PCIs listed in the questionnaire as possibly being 
identifiable before provision of the I-MUR, with those selected most frequently being inappropriate 
administration of drug (58.1%), potential/actual compliance/concordance/adherence issue (50%) and 
duration of therapy (41.8%) See Figure 1. Two types of PCI were considered to have been found more 
frequently after delivering the service than had been anticipated; these were potentially ineffective 
therapy, which was anticipated by 22% (n=11) but found by 45% (n=22) of respondents, and 
potential/actual need for education about medicines, anticipated by 47% (n=23) but found by 55% (27) 
(p=0.06). For most types of issues fewer respondents in the post I-MUR Q judged they had been found 
compared to what was anticipated, most notably fewer pharmacists (18; 37%) identified 
potential/actual compliance/concordance/adherence issues than anticipated (37; 76%) (p<0.01). 
Pharmacists anticipated they would provide education on inhaler technique (47; 96%) and medication 
counselling (47; 96%) most frequently but they confirmed that these two types of intervention were 
actioned by 44 (90%) and 43 (86%) respectively). Referrals to prescribers were higher than anticipated 
(43& versus 29%), whereas asking prescribers to amend doses, providing information to prescribers 
and referrals to other health professionals were all identified as occurring less frequently than 
anticipated. 
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Figure 1 Pharmaceutical Care Issues anticipated before and experienced during provision of I-MURs 
 
 
9 
 
Pharmacists’ perceptions of I-MUR before and after provision 
Most pharmacists felt comfortable with their involvement in the I-MUR service before it started, while 
the majority considered they needed a little more knowledge/skills (Table 2). Knowledge and skills 
increased after delivery, but the number requiring more knowledge also increased slightly. All agreed 
both before and after delivery that the I-MUR could improve patients’ use of medicines, but several 
were less convinced about its value in extending their role and enhancing patients’ understanding of 
their medicines than they had been prior to delivering the service.  
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Table 2 Pharmacists’ perceptions of I-MUR service before and after provision  
 
  
Pre I-MUR Q  Post I-MUR Q 
Pharmacists’ perceptions 
N N Strongly 
agree/agree 
N 
Neither 
agree 
nor 
disagree 
N Strongly 
disagree/disagree 
   N Strongly 
agree/agree 
N Neither 
agree nor 
disagree 
N Strongly 
disagree/disagree 
Providing I-MURs is an opportunity to extend your 
role and make better use of your professional 
judgement 
49 48 1 0 
 
47 2 0 
I-MUR services will enhance pharmacists 
understanding of their patients view on medicines. 
49 48 1 0 
 
44 5 0 
Providing I-MURs is a waste of time for me. 48 0 5 43 
 
0 2 46 
Providing I-MURs is a waste of time for my patients. 48 0 1 48 
 
1 3 44 
I-MURs can improve patients’ use of medicines. 49 49 0 0 
 
49 0 0 
 
  Confident Little 
/more 
needed 
Much more 
needed 
  Confident Little 
/more 
needed 
Much more 
needed 
Do you feel you have enough knowledge to carry 
out the I-MUR service? 
49 2 46 1 
 
4 42 3 
Do you feel you have enough skills to carry out the 
I-MUR service? 
49 7 41 1 
 
12 33 3 
 
  Very/fairly 
comfortable 
Neutral Some 
reservations 
  Very/fairly 
comfortable 
Neutral Some 
reservations 
Do you feel comfortable with your involvement in 
the I-MUR service? 
49 40 5 4 
 
44 3 2 
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Pharmacist focus groups  
The results are presented under the six main topic areas used in the topic guide.  
a) Feedback from patients  
The feedback which pharmacists reported receiving from patients for whom they had provided an I-
MUR was positive in all nine focus groups across all four locations, confirming that the project was well 
received by their patients.  
“We achieved great results in our pharmacy, one of our patients who came from Morocco told me that 
I was the first health care practitioner explaining how to use his asthma medication”. (Treviso FG2) 
Pharmacists themselves considered that the I-MUR service was very useful in improving patient’s use 
of their medication and comments from patients endorsed this. 
“I have to say that patients who participated in the study were very happy, they felt involved and came 
back telling me that they had improved and they were feeling better” (Torino FG) 
 “I received a very good feedback from one of my patients; before the I-MUR consultation he did not 
know how to use salbutamol inhaler, after the consultation the patient confirmed that his inhaler 
technique has improved”. (Treviso FG1) 
 There was a view that elderly people wanted more attention and wanted pharmacists to listen to their 
experiences of using medicines. 
b) Pharmacists’ view about I-MUR 
The project as a whole was rated as very interesting, with a completely different approach towards the 
patient compared to usual Italian pharmacy practice. The pharmacists were enthusiastic and suggested 
that this was the right way for pharmacists to practise. Some expressed pride when conducting the I-
MUR interview, suggested also to organise meetings between pharmacists who provided the I-MUR 
service and the ones who did not to enable sharing of experience and best practice. 
Although the I-MUR service was perceived by pharmacists as a great opportunity to provide a new 
service in a systematic and structured way, it was also seen as a challenging experience. Most 
pharmacists however confirmed that they felt comfortable providing the service, but the aim of the 
intervention needed clarification. 
 “I see I-MUR as a very useful tool for patient follow up, but I cannot see it as a tool for changing 
therapy”. (Treviso FG2) 
c) Limitations for providing the I-MUR  
Time management was one of the most common limitations raised across all the focus groups. The 
speed at which prescriptions and counselling have to be dispensed /given to patients could often play 
a big role, because some patients did not want to wait and therefore were not able to attend the I-
MUR session. Some pharmacists were organised and looked at the items/prescription they had 
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previously dispensed to identify potential I-MUR candidates, making phone calls to book an 
appointment. Some pharmacists highlighted they did not feel confident in providing the I-MUR service 
because of lack of experience. In one FG time was raised as a limiting factor, while in another the 
suggestion was made that all staff should be involved and all pharmacists should be trained in the I-
MUR intervention. 
The layout of pharmacy premises was also described in more than one FG as not being structured for 
this type of service. 
d) Possible barriers to providing the I-MUR  
It was clear from FG discussions that this project was essentially defining a new role for the pharmacists 
who provided the I-MUR. The information flow between community pharmacists and GPs was 
identified as one of the main barriers. GPs seemed not to get very much involved in I-MURs, but did 
not discourage pharmacists who wanted to provide it.  Hospital consultants in asthma care, who were 
involved in training, in contrast were perceived as supporting pharmacists who provided the I-MUR. 
Some pharmacists who worked in an area with lots of immigrants found difficulties in communication 
because of the language barrier, while recognising that this could play an important role in adherence 
to treatment.  
e) Views on the training provided 
The vast majority of pharmacists appreciated the training provided, and recognised the need for 
specific training in order to provide this intervention. Only one pharmacist in one focus group 
suggested that the training was not enough. Some pharmacists added that it was like a revaluation of 
the profession, explaining that since they qualified 15 or more years ago, their university education 
had not provided them with the background needed.  
“I do not feel that I have enough knowledge and I believe that the training that I received from the 
university was not adequate”. (Brescia FG1) 
There was a view that new teaching models, subjects and syllabi are needed more aligned with the 
new health care requirements, suggesting that I-MUR could be the beginning of an implementation 
programme for university education too. Pharmacists confirmed that even now advanced pharmacy 
services such as this are not taught at university level in Italy.  
“This is music for my ears, we need a much better training which must begin at undergraduate level; 
the Italian University has to change!” (Pistoia FG2) 
f) Possible applications and developments 
The provision of training and a clear protocol on how to provide the I-MUR service was welcomed by 
many participants and regarded as necessary for successful delivery. Pharmacists’ expectations were 
that the I-MUR would be extended to other clinical areas.  
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“provide a structured training package for other diseases as well” (Pistoia FG1) 
All groups agreed that I-MUR was about professionalism; this activity could enhance their professional 
status allowing them to share best practice and information with GPs. 
Patient views 
The demographic details of patients who received the I-MUR are shown in Table 3, along with those 
of questionnaire respondents. There were high proportions of questionnaires received from Brescia 
and fewer from Torino, however in terms of age and gender, the respondents were representative of 
the population who received the I-MUR. One patient did not submit demographic information. 
 
 
Table 3 Demographic characteristics of patients (n=245) 
 
Patients characteristics   Had I-MUR  Provided feedback 
    N(%) N(%) 
Place of residence (n=245) Brescia 202(22.5) 76(31) 
 Pistoia 259(28.9) 68(27.6) 
 Treviso 224(25.1) 63(25.7) 
 Torino 210(23.5) 38(15.5) 
       
Gender (n=245) Male 404(45.1) 106 (43.3) 
 Female 419(54.9) 139 (56.7) 
        
Age (n=244) 18-30 87(9.7) 20(8.2) 
 31-40 83(9.3) 20(8.2) 
 41-50 128(14.3) 26(10.7) 
 51-60 146(16.3) 48(19.7) 
 61-70 185(20.7) 51(20.9) 
 71-80 185(20.7) 58(23.8) 
 >80 78(8.7) 21(8.6) 
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Views and experiences of I-MUR 
Seven potential benefits of the I-MUR were provided in the questionnaire from which patient 
respondents could select. The benefit selected most frequently was “make sure that I am using my 
medications correctly”, (151; 62.9%), however four of the potential benefits were selected by fewer 
than half the respondents. (Table 4.) 
 
 
Table 4 Perceived benefits from having an I-MUR 
 
How did you hope to benefit from the I-MUR? (Please tick 
any options you feel are important) N 
% of patients who 
selected the 
statement 
Make sure I am using my medications correctly 151 62.9 
Find out more information about my medications 146 60.8 
Find out more information about my medical conditions 120 50.0 
Understand exactly what each of my medications is for 108 45.0 
Discuss any side effects of my medications 92 38.3 
Become more involved in my own health care 74 30.8 
 
  Discuss any problems / concerns with my medications                 70              29.2  
 
 
Experiences of the I-MUR are shown in Table 5. Only around a quarter of patients agreed/strongly 
agreed that they were worried about their medications (25.4%) or had problems with asthma (24.0%) 
before I-MUR, but three-quarters (75.2%) agreed they benefited from having the I-MUR and 84.1% 
were happier with their medications after the I-MUR. In addition, almost all agreed with statements 
relating to the conduct of the I-MUR.  Most also confirmed that the I-MUR met their expectations 
(88.0%). More respondents (89; 37.4%) strongly agreed/agreed that I-MUR found problems with their 
medications than considered they had problems beforehand, and 63 (25.6%) that changes were made 
to their medications after I-MUR. There were 43 (18.5%) who strongly agreed/agreed with both 
statements and a statistically significant positive association was found (γ = 0.70, p < 0.01), between 
problems identified and medication changes. While 84.1% of patients agreed they were happier with 
their medications after the review, there were 41 (17.8%) who agreed they still had questions about 
their medications which were not answered during the I-MUR. 
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Table 5 Patients’ reported experiences of the I-MUR (n=245) 
 
Questions N 
% Strongly 
agree/agree 
% Not 
sure 
% Strongly 
disagree/disagree 
 I was worried about my medication 
before I went for the I-MUR 
236 25.4 21.2 53.4 
I had problems with my asthma before I 
went for the I-MUR 
233 24.0 19.7 56.3 
The pharmacist put me at ease 245 99.2 0.8 0.0 
The I-MUR was done in a suitable place 239 97.0 1.7 1.3 
There were no interruptions during the 
I-MUR 
239 93.3 2.9 3.8 
I had the full attention of the 
pharmacist during the I-MUR 
244 98.8 1.2 0.0 
The pharmacist wanted to help me deal 
with any concerns I had about my 
medications 
241 96.3 2.5 1.2 
I felt that I was given enough time for 
the I-MUR 
239 94.1 5.8 0.4 
I felt comfortable asking any questions I 
had about my medication 
240 93.8 5.8 0.4 
I understood everything discussed 
during the I-MUR 
237 85.2 13.1 1.7 
I feel I benefited from having the I-MUR 238 75.2 18.9 5.9 
The pharmacist answered all my 
questions to my satisfaction 
242 96.7 2.5 0.8 
The I-MUR found problems with my 
medications 
238 37.4 18.5 44.1 
Changes were made to my medications 
after the I-MUR 
232 27.2 13.8 59.0 
I felt involved in all of the decisions 
made about my medications 
232 75.4 17.2 7.4 
I still have questions about my 
medications which were not answered 
231 17.6 27.7 54.7 
I was given the opportunity to discuss 
any problem I had during the I-MUR 
233 89.7 7.7 2.6 
The I-MUR met my expectations 234 88.0 10.7 1.3 
I am happier with my medications after 
my review 
233 84.1 12.5 3.4 
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There were 46 (19.2%) patients who felt that the I-MUR could be improved, however most of the 
suggestions related to expansion of this as a service. These included: bringing together more patients 
to share their experience, expanding the I-MUR service provision to other diseases, involving more 
pharmacies in the provision of this service, and giving feedback more often and more regularly, three 
months was mentioned by many patients. A small number suggested more time was needed for the 
interview, more information should be provided regarding I-MUR and the use of their medicines, and 
more focused questions used. 
“More focused questions for spotting therapy errors” [P55, Brescia, female, age 31-40]. 
There were 121 (51.3%) who would consider having another I-MUR, although 16.9% (40) would not 
and 31.8% (75) did not know (10 missing). Reasons for not wanting to have another were given by 11 
patients, which included the view that one was enough, being well managed by their health care 
professionals and in one that I-MUR did not help. 
A very high proportion of patients indicated they would recommend the I-MUR service to other people 
(200; 85.5%), with only 2.1% (5) indicating they would not and 12.4% (29) who didn’t know (12 
missing). Reasons given for positive recommendations were: they found it useful, pharmacists focused 
attention mostly on them and not on drugs, and improving knowledge about the medications will also 
improve knowledge about their disease.  
 “The service is very useful for the information provided; because we need to take the medications, 
there are no other choices.” [P200, Treviso, male, age 31-40] 
Free-text comments also showed that patients appreciated the information given by the pharmacists, 
their competence, knowledge, and availability to discuss their health care issues;  
One patient stated that the I-MUR service was  
“The best and fastest medication I never had” [P101, Torino, female, age 51-60] 
Discussion 
The pre and post I-MUR Q revealed that pharmacists’ views on the I-MUR changed after they had 
provided it in that confidence increased and the lack of financial compensation initially anticipated did 
not seem to be a major barrier in practice. Although lack of coordination and collaboration with GPs 
was highlighted both before and more so after delivery of the I-MUR, pharmacists wanted to overcome 
this, through sharing best practice and information with GPs. The pharmacist survey respondents felt 
that the I-MUR could improve patients ‘use of medicines and those attending focus groups illustrated 
this with examples they had received. This was confirmed by the findings from the patient survey, 
which indicated a high proportion of those who responded considered their I-MUR was beneficial and 
were happier with their medications afterwards. Pharmacists considered that this was a service which 
could enhance their professional status, that cognitive services such as this were the right approach 
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for the development of the future of the pharmacy profession in Italy and that I-MUR should be 
extended to other medical conditions, but that specific training was required. Patients too suggested 
extending the service to more conditions and to more pharmacies. The training provided for the I-MUR 
provision was generally considered sufficient, but the need for redirection of the undergraduate 
pharmacy programme in Italy in order to increase clinical knowledge was also highlighted.  Most 
pharmacists felt they had sufficient skills to deliver this as a service and the patient survey indicated 
high levels of satisfaction with the processes. Positive patient views on similar medication review 
services have been found in several studies. A large randomised controlled trial in England (2007)4 
found that patients’ satisfaction with the service provided by their pharmacist and likelihood of asking 
questions of their pharmacist increased significantly after receiving a medication review in the 
intervention group compared with controls. Other studies in England have reported patients’ 
appreciation of and positive views towards the MUR service,6,15 with one reporting an increase in 
understanding of both medicines and conditions.16 An evaluation of the English MUR service found 
that patients felt comfortable speaking with the pharmacist, whom they saw as a knowledgeable 
expert on medicines. This was also apparent in our patient survey, almost all of whom confirmed that 
pharmacists answered all their questions to their satisfaction, and from the feedback provided to the 
pharmacists themselves. Despite the positive views, there was a significant proportion (18%) of 
patients who still had questions about their medications, which was also found in a small evaluation 
of the English MUR using the same questionnaire.14 While the most likely explanation for this is that 
patients thought of additional questions after the I-MUR had been completed, particularly given the 
time interval between the I-MUR and the patient survey, pharmacist knowledge may have been 
insufficient. Pharmacists’ perceptions of their skills and knowledge was in fact high even before they 
started to deliver the I-MUR, in contrast to pharmacists in England prior to delivering a similar service 
(Jaffray et al. 2007),12 and while pharmacists in this latter study did perceive their skills and knowledge 
improved after training, there was no significant change in the perceived skills and knowledge of the 
pharmacists delivering the I-MUR. The need for more communication and collaboration with GPs 
regarding the medicines use review (MUR) service in England has been reported.178 Latif et al. (2013) 
have also suggested that a closer collaboration between GPs and pharmacists could potentially 
improve patients’ use of medicines and associated health care outcomes.18 In practice, the I-MUR 
resulted in pharmacists not only providing advice to patients, but also to GPs with regards to patient’s 
medicines and asthma control (unpublished data), hence the service may have resulted in increased 
contact.   
In addition to the need for greater co-ordination with other health professionals, Italian pharmacists 
indicated that lack of time was both a potential and actual barrier. This was also found in a study which 
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examined the first year of a MUR service in New Zealand.19 In New Zealand the lack of contact with 
funders was also an issue, in contrast to the present study in which lack of funding did not appear to 
be a limiting factor. A few pharmacists suggested that the pharmacy lay out and premises were not 
structured for this new service, although only 1% of patients suggested that the I-MUR was not done 
in a suitable place. In fact, a private area was a requirement for involvement in the study, but the 
extent to which these are available in Italian pharmacies in general is not known. The MUR service in 
England was one of the driving forces behind the development of private consultation areas in 
community pharmacies, which are now present in over 90% of pharmacies in England (PSNC, 2016).20 
Despite this, lack of privacy has been cited as a perceived obstacle to service utilization in England, 
along with competencies and confidentiality, due to a lack of awareness of the availability of private 
consultation rooms in community pharmacies among the public.21  
Strengths and limitations 
The questionnaires used were adapted from the literature and other studies, allowing comparisons to 
be made. Both service providers and service users were included in this evaluation, with the patient 
survey purposely conducted nine months after the I-MUR service ended, thus allowing time for 
reflection on their experiences. However, this lengthy time interval may have affected recall. A large 
number of pharmacists providing the I-MUR who participated in the focus groups, although slightly 
fewer completed both evaluation questionnaires. The questionnaire response rate for pharmacists 
was 66%, but for patients was 27%, thus may reflect those with positive views. 
Conclusion 
The I-MUR service was perceived positively by pharmacists and patients, hence was acceptable to both 
stakeholder groups. Community pharmacists have the potential to become more involved in delivering 
cognitive services, which so far has been under-utilised within the Italian primary health care system. 
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